12:41 PM
 | 
May 16, 2019
 |  BC Extra  |  Company News

Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver diseases and celiac disease.

Parvus Therapeutics Inc. (Burlingame, Calif.) believes Navacims could offer a comprehensive solution for chronic inflammatory conditions. By transforming T cells targeting self-antigens into Tregs that dampen the immune response, the...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >